Efficacy and safety of obicetrapib in patients with dyslipidemia: An updated meta-analysis of randomized controlled trials.

ABSTRACT:

Introduction

Obicetrapib is a novel cholesteryl ester transfer protein (CETP) inhibitor with promising lipid-lowering effects. While earlier CETP inhibitors have shown inconsistent cardiovascular outcomes and safety concerns, the efficacy and safety of obicetrapib remain under active investigation.

Methods

We systematically searched PubMed, Embase, and Cochrane Central databases for randomized controlled trials (RCTs) comparing obicetrapib versus placebo in adults with dyslipidemia or at high cardiovascular risk. We pooled mean differences (MDs) with 95 % confidence intervals (CI) with a random effects model. We used R software version 4.4.2 for statistical analysis.

Results

We included 7 RCTs comprising 3381 participants, of whom 2151 (63 %) received obicetrapib. The

SUBMITTER: Araujo B 

PROVIDER: S-EPMC12528909 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature